Rhythm Pharmaceuticals, Inc. (RYTM) News
Track canonical SquawkNews coverage tagged to RYTM, Rhythm Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
RYTM - Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
RYTM - Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
EARNINGS | Aug 04, 2026, 01:33 PM UTC
H
Rhythm Pharmaceuticals Reports Positive Efficacy Signal
Rhythm Pharmaceuticals shows positive efficacy in phase 2 trial
EQUITY | Aug 04, 2026, 10:55 AM UTC
L
RYTM Initiated Overweight W/$145.00 PT at JPMorgan
RYTM Initiated Overweight W/$145.00 PT at JPMorgan
EQUITY | Jul 27, 2026, 12:08 PM UTC
L
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH
EQUITY | Jul 27, 2026, 11:09 AM UTC
L
RYTM Reiterate Market Outperform, $155 PT following HO survey for Imcivree @ Citizens
RYTM Reiterate Market Outperform, $155 PT following HO survey for Imcivree @ Citizens
EQUITY | Jul 14, 2026, 11:37 AM UTC